Biotech Values

[mcbio]

ABBV/ENTA’s Maviret* approved in Canada

Dew, I'm assuming ENTA hasn't given any rough guidance on expected royalties from Mavyret/Maviret for 2018. Do you have any thoughts on what to expect here for 2018? I freed up a little cash and just kicking tires on a lot of names to see what I want to play next. Seems like HCV can provide a nice floor for the stock going forward at a minimum and possibly decent upside depending on expectations then you have the rest of the pipeline that could drive upside depending on results.